ANI Pharmaceuticals

In two facilities with combined manufacturing, packaging and laboratory capacity exceeding 170,000 sq. ft., ANI develops and manufactures liquid, powder and oral solid dose products, including those requiring containment. ANI also performs contract manufacturing for some of the largest and most respected pharmaceutical companies in the world. The fully-cGMP qualified facilities boast state-of-the-art analytical and stability laboratories for ANI's rapidly expanding research and development program. With several ANDAs pending FDA approval, and in various stages of development, ANI is poised for tremendous growth in the months and years to come!
Company Growth (employees)
Type
Public
HQ
Baudette, US
Size (employees)
143 (est)
ANI Pharmaceuticals is headquartered in Baudette, US

ANI Pharmaceuticals Office Locations

ANI Pharmaceuticals has an office in Baudette
Baudette, US (HQ)
210 Main St W
Baudette, US
455 Idc Rd SW

ANI Pharmaceuticals Data and Metrics

ANI Pharmaceuticals Financial Metrics

ANI Pharmaceuticals's revenue was reported to be $36.6 m in Q1, 2017
USD

Revenue (Q1, 2017)

36.6 m

Gross profit (Q1, 2017)

20.2 m

Gross profit margin (Q1, 2017), %

55%

Net income (Q1, 2017)

1.2 m

EBIT (Q1, 2017)

4.6 m

Market capitalization (21-Sep-2017)

594.1 m

Cash (31-Mar-2017)

10.8 m
ANI Pharmaceuticals's current market capitalization is $594.1 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

30.1 m56 m76.3 m128.6 m

Revenue growth, %

86%36%69%

Cost of goods sold

10 m11.5 m12.7 m48.8 m

Gross profit

20.1 m44.5 m63.6 m79.8 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

6.6 m17.4 m18.8 m19.5 m20 m20.6 m31.3 m38.5 m36.6 m

Cost of goods sold

2.1 m3.1 m2.8 m3.1 m3.3 m3.4 m11.8 m16.7 m16.4 m

Gross profit

4.5 m14.3 m16 m16.4 m16.7 m17.1 m19.5 m21.9 m20.2 m

Gross profit Margin, %

68%82%85%84%84%83%62%57%55%
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

11.1 m169 m154.7 m27.4 m

Accounts Receivable

12.5 m17.3 m21.9 m45.9 m

Inventories

580 k1.1 m1.5 m26.2 m

Current Assets

27.7 m203.5 m192.6 m103 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

53 m35.1 m165.6 m166.7 m150.9 m77.7 m15 m16.2 m10.8 m

Inventories

5.9 m7.3 m10.7 m12.7 m13.7 m13.9 m25.1 m28.3 m45.9 m

Current Assets

67.2 m57.6 m203 m208.9 m197.5 m116.6 m79.8 m95.5 m107 m

PP&E

4.6 m5 m5.3 m5.2 m5.8 m8.4 m8.9 m9.7 m12.9 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

301 k28.7 m15.4 m3.9 m

Depreciation and Amortization

1.1 m3.9 m6.9 m22.3 m

Accounts Receivable

(7.1 m)(4.8 m)(4.6 m)(24 m)

Inventories

(708 k)(3.5 m)(314 k)(647 k)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

6.7 m4.4 m3.6 m4.6 m1.3 m1.1 m2.5 m1.2 m

Depreciation and Amortization

706 k1.2 m1.3 m1.4 m2 m4.6 m6 m6 m6.7 m

Accounts Payable

1.7 m3.1 m2.3 m1.3 m2.6 m3 m5 m4.7 m4.8 m
USDY, 2017

Revenue/Employee

256.1 k

Financial Leverage

2.1 x
Show all financial metrics

ANI Pharmaceuticals Market Value History

Traffic Overview of ANI Pharmaceuticals

ANI Pharmaceuticals Company Life and Culture

You may also be interested in